Veradermics priced an upsized $256.3 million IPO to finance pivotal phase II/III studies of VDPHL‑01, an oral formulation of minoxidil developed to avoid cardiovascular risks of prior systemic approaches. The New Haven-based dermatology biotech will use proceeds to complete three pivotal trials and move toward regulatory dossiers for pattern hair loss in men and women. The strong execution highlights investor interest in late-stage, specialty dermatology programs with near-term clinical inflection points.